To determine the incidence of chemotherapy-induced nausea/vomiting (CINV) and chemotherapy treatment delay and adherence among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT 3 RA) antiemetics.
Introduction
Nausea and vomiting are common chemotherapy-associated side effects ranked by patients as especially distressing. [1] [2] [3] [4] [5] [6] [7] Chemotherapy-induced nausea and vomiting (CINV) can cause psychological distress, nutritional deficiencies, and reduced quality of life among patients receiving chemotherapy. [5] [6] [7] [8] Furthermore, its occurrence may potentially affect adherence to chemotherapy regimens, leading to treatment delays or receipt of fewer treatments or lower dosages than recommended. 9, 10 Such events may have an adverse effect on treatment efficacy, ultimately resulting in suboptimal clinical outcomes and potentially increased health care-related resource utilization and costs. 3 Recognizing the importance of preventing and managing CINV, leading oncology societies have issued treatment guidelines [11] [12] [13] 29 recommending 5-hydroxytryptamine-receptor antagonists (5-HT 3 RAs) as the preferred medication class to effectively prevent CINV in patients receiving highly emetogenic chemotherapy (HEC) or moderately EC (MEC). 19, 20 Compared to the older agents, palonosetron -a newer 5-HT 3 RA -is pharmacologically distinct, with a longer half-life and greater receptor-binding affinity, allosteric binding to serotonin receptors with positive cooperativity, and cross talk with Neurokinin-1 (NK-1) receptors. [21] [22] [23] While the early 5-HT 3 RA compounds were considered equally efficacious, 19 palonosetron demonstrated greater efficacy than active comparators in preventing CINV in patients receiving HEC or MEC in multiple clinical trials. 20, [24] [25] [26] Hatoum et al compared palonosetron with other 5-HT 3 RAs in a real-world setting among patients with breast/lung cancer undergoing cisplatin/ carboplatin treatments. 19, 27 They concluded that patients who received prophylaxis with palonosetron had a significantly lower risk of CINV events than those who had received other 5-HT 3 RA agents. Furthermore, those breast/lung cancer patients receiving palonosetron experienced 49.5% and 29.1% fewer CINV days, respectively. 27 Their study focused on serious CINV events resulting in hospital or emergency department admissions, and did not include CINV events occurring in an outpatient context. Craver et al found that prophylactic administration of palonosetron among patients with hematologic malignancies who were receiving HEC/ MEC resulted in a 20.4% decrease in CINV event rate per cycle compared with patients receiving other 5-HT 3 RAs. 28 However, while 5-HT 3 RA agents have been proven effective in preventing CINV, little is known regarding their impact on chemotherapy treatment adherence and delay. To address these questions, a real-world study was designed comparing patients who received palonosetron with those who received other 5-HT 3 RAs on incidence of acute and delayed CINV and chemotherapy treatment delay and adherence. This study also contributes to the development of methods to assess medication adherence for intravenous (IV) agents.
Materials and methods
This was an observational nested case-control study using data from the HealthCore Integrated Research Database (HIRD SM ). The HIRD is an integrated medical and pharmacy-claims and laboratory-result database of commercially insured patients from 14 major commercial health plans across the US representing approximately 45 million patient-lives dating as far back as January 1, 2001.
Cohort creation
The index date was defined as the earliest medical or pharmacy claim date for an IV HEC or MEC between January 1, 2002 and October 31, 2010. All patients included in the study were adults ($18 years of age as of the index date) who had one or more medical claims with a diagnosis of primary malignant breast, lung, or colorectal neoplasm during the baseline period, which was defined as the 12 months before the index date. All patients had continuous medical and pharmacy health plan eligibility for at least 12 months pre-and 12 months postindex date. Patients were excluded if they 1) had a secondary malignant neoplasm or primary neoplasms at multiple sites, 2) had preindex HEC or MEC claims, 3) initiated multiday chemotherapy, 4) received oral chemotherapy alone or in combination with an IV formulation, 5) switched from a single-day-per-cycle chemotherapy regimen to multiday chemotherapy, or 6) had medical claim(s) for pregnancy, labor, or delivery in the 6 months postindex. Lastly, in order to create clean comparison cohorts, patients receiving both palonosetron and any of the "other" 5-HT 3 RAs any time during the course of one or more chemotherapy treatment cycles were excluded from the analysis. The remaining patients were stratified into either the palonosetron or other 5-HT 3 RA treatment cohorts. Specifically, patients in the palonosetron group received only palonosetron and no other IV 5-HT 3 RA agent (ie, dolasetron, granisetron, and/or ondansetron; see Table S1 ) as prophylactic or rescue therapy beginning 1 day before through 5 days after the start of any chemotherapy treatment cycle; those in the other 5-HT 3 RA cohort were allowed to receive any prophylactic 5-HT 3 RA agent other than palonosetron.
assignment of chemotherapy regimens
Index HEC and MEC agents were defined as any chemotherapeutic agent classified as having a known high or moderate emetogenic potential (Table S2) . 29 Chemotherapy agents were identified using generic product identifier (GPI) and Healthcare Common Procedure Coding System (HCPCS) codes. Chemotherapy dose determined the HEC/MEC status of certain chemotherapy drugs (eg, cyclophosphamide and cisplatin) by calculating the index dose administered and then applying the National Comprehensive Cancer Network (Table S3) . 29 Because only singleday administration regimens were included in the study, the average dose was equal to the average strength, as noted on medical or pharmacy claims. Body-surface area (BSA) was not available on claim forms, so published BSA estimates of cancer patients were used to determine the average dose per square meter. 30 The For regimens involving a combination of chemotherapeutic agents, the agent with the highest emetic risk defined the risk of the combination (ie, one MEC agent and one HEC agent equaled an HEC regimen; one lowly EC [LEC] and one MEC equaled an MEC regimen). 12, 13 Two MEC agents were classified as HEC; however, two LEC agents remained a lowly emetogenic regimen (Table 1) . 31 Additional information on the step-by-step regimen identification can be found in the Supplementary materials.
Claims for index chemotherapy agents dated 7 days or later after the beginning of the cycle were designated as the beginning of the subsequent cycle, and so on until the end of the 12-month observation period. The end of a chemotherapy cycle was determined using either the passing of the NCCNrecommended number of weeks between two cycles (Table 2) , which was specific to each treatment regimen, or the start date of the subsequent treatment cycle, whichever occurred earlier.
Outcome measures
Acute CINV was identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for nausea and vomiting, persistent vomiting, or volume depletion, or current procedural terminology codes for hydration, on the day of chemotherapy (Table S1 ). Delayed CINV was identified by the same ICD-9-CM and CPT codes for nausea and vomiting, volume depletion and hydration, as well as GPI/HCPCS codes for IV rescue medications (dexamethasone, fosaprepitant, diphenhydramine, promethazine, haloperidol, prochlorperazine, lorazepam, or metoclopramide) or 5-HT 3 RAs (Table S1 ) between the day after chemotherapy and day 5 of the chemotherapy cycle of interest. CINV events were assessed on a patient-and cycle-level basis.
Each index chemotherapy regimen was assigned a total number of chemotherapy cycles and an allowed gap between chemotherapy cycles according to the recommendations of the 2011 NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines ® ) ( Table 2 ). [14] [15] [16] [17] [18] For example, a lung cancer patient on cisplatin (index dose of 100 mg/m 2 ) and vinorelbine would be assumed to have initiated a therapy involving four treatment cycles with an allowed rest period of 4 weeks between each cycle.
Treatment delay was measured in two ways: 1) the proportion of patients who delayed their index chemotherapy based on the presence of a significant gap between two chemotherapy cycles, and 2) the mean and median time from the index date to the date of treatment delay. Delay of therapy was defined as a gap in treatment exceeding twice the NCCNspecified cycle length specific to each chemotherapy regimen ( Table 2 ). The date of treatment delay was the date of the last chemotherapy cycle start date prior to delay plus one cycle length. For patients on combination regimens, delay of any one agent involved in the regimen constituted delay of the entire regimen. We also performed a sensitivity analysis around the permissible treatment gap, assigning a lower limit of 1.5 times the NCCN-recommended cycle length and an upper limit of three times the NCCN-recommended cycle length.
Treatment adherence was measured in four related ways: the percentage of patients who received the 1) recommended number of cycles for their specific chemotherapy regimen, as determined by NCCN guidelines, 2) recommended number of chemotherapy cycles for their regimen within the recommended time frame, 3) recommended chemotherapy dose within a 10% margin, and 4) recommended number of cycles within the specified time frame at the expected dose. We used measure 2 as our primary measure of adherence. Patients on multiagent regimes were required to be adherent with each component of the regimen to be considered adherent overall.
statistical analysis
Descriptive statistics were used to characterize the incidence of acute and delayed CINV, as well as baseline patient characteristics, such as primary cancer site and chemotherapy regimen. Means/standard deviations were used for Cyclophosphamide ( Carboplatin (150-900 mg/m 2 ) + gemcitabine MeC continuous data, and counts/relative frequencies were used for categorical data. Each baseline characteristic and study outcome was compared using unadjusted statistical tests between patients receiving palonosetron and those receiving all other 5-HT 3 RAs. Continuous variables were compared using Student's t-test or Wilcoxon rank-sum test, depending on the distributional characteristics. Categorical data were compared using χ 2 tests.
Logistic regression models were used to estimate associations between antiemetic treatment (palonosetron versus other 5-HT 3 RAs) and CINV (acute and/or delayed), delay of index chemotherapy regimen, and adherence to index chemotherapy regimen. and baseline receipt of LEC, radiation, and antiemetics. All analyses were stratified by HEC and MEC regimens.
Results

Patient characteristics
We identified 1,832 HEC patients who received only palonosetron and no other 5-HT 3 RA and 2,387 HEC patients who received other 5-HT 3 RAs excluding palonosetron (Table 3 ). In the HEC group, the mean age was slightly higher among palonosetron users (52.0 versus 51. 4 
Chemotherapy treatment delay
Fewer chemotherapy treatment delays occurred among patients receiving palonosetron compared with other 5-HT 3 RAs in both the HEC (3.2% versus 6.0%, P,0.0001) and MEC (17.0% versus 26.8%, P,0.0001) cohorts (Table 4) . The results for delayed therapy remained consistent when using the upper and lower limits as defined earlier (see Table 4 ). Mean time to delay was similar across the palonosetron and other 5-HT 3 RAs groups (approximately 76 days in the HEC cohort and 86 days in the MEC cohort).
Chemotherapy treatment adherence
In both the HEC and MEC cohorts, more patients receiving palonosetron were adherent to their chemotherapy regimen compared to those who received other 5-HT 3 
Discussion
In this retrospective, observational, nested case-control study, patients who received prophylactic or rescue palonosetron had significantly fewer CINV events, fewer chemotherapy e pulmonary disease included asthma, bronchitis, pneumonia, emphysema, and COPD. Abbreviations: hT, hydroxytryptamine; Ras, receptor antagonists; heC, highly eC; MeC, moderately eC; leC, lowly eC; neC, non-eC; eC, emetogenic chemotherapy; sD, standard deviation; hMO, health maintenance organization; POs, point of service; PPO, preferred provider organization; FFs, fee for service; na, not applicable; Q, quartile; COPD, chronic obstructive pulmonary disease; DCi, Deyo-Charlson Comorbidity index. Abbreviations: hT, hydroxytryptamine; Ras, receptor antagonists; heC, highly eC; MeC, moderately eC; eC, emetogenic chemotherapy; CinV, chemotherapy-induced nausea/vomiting; sD, standard deviation; Q, quartile.
treatment delays, and higher adherence to their chemotherapy regimen compared with patients who received any other IV 5-HT 3 RA medication. These findings were seen both among patients who were undergoing HEC treatment and those undergoing MEC treatment.
Results from clinical trials have demonstrated the overall efficacy of palonosetron in preventing acute CINV in patients receiving HEC and in preventing acute or delayed CINV in patients receiving MEC. 20, [24] [25] [26] However, limited evidence is available regarding the effect of palonosetron on chemotherapy adherence and treatment delay in a real-world setting. To our knowledge, no previous study has evaluated this association. A previous administrative claims analysis evaluated the risk of serious CINV events associated with Notes: For CinV and delayed therapy, an odds ratio ,1 is associated with improved outcomes; for adherence, an odds ratio .1 is associated with improved outcomes. Abbreviations: hT, hydroxytryptamine; CinV, chemotherapy-induced nausea/vomiting; heC, highly eC; MeC, moderately eC; eC, emetogenic chemotherapy.
hospital or emergency department admissions among patients with breast or lung cancer undergoing MEC or HEC who received palonosetron compared with those who received any other 5-HT 3 RA. 19 Patients receiving palonosetron experienced a significantly reduced risk of serious CINV compared to those who received other 5-HT 3 RAs, ranging from 31% to 45% among lung and breast cancer patients, respectively. Another recent study by Craver et al evaluated the risk of CINV among recipients of palonosetron versus other 5-HT 3 RAs initiating HEC/MEC therapy in all medical settings, 28 using a broader definition of CINV encompassing events occurring any time within 7 days of the chemotherapy cycle-start date. While both studies showed a reduction in CINV with palonosetron use as expected, an exploration of the effect of CINV risk reduction on chemotherapy adherence or delay was not conducted.
The real-world analysis in the current study demonstrated improved adherence to chemotherapy regimens among patients who received palonosetron compared with other 5-HT 3 RA agents. The association between the use of antiemetics and adherence may have been underestimated: patients undergoing chemotherapy, particularly HEC, are more likely to have been prepared by their health care providers to expect nausea and vomiting; such preparedness has been shown to alleviate the reported incidence of nausea and vomiting in patients receiving chemotherapy. 31 Additionally, some patients undergoing IV chemotherapy regimens will have advanced disease, and may therefore not have the option of delaying or discontinuing treatment because of nausea and vomiting. 33 Future research exploring the association between reduced CINV and chemotherapy adherence would benefit from a cost analysis, which was not included in the current study. A therapy that improves chemotherapy adherence by reducing CINV events could potentially reduce costs, both direct (costs of antiemetic medications, physician visits, and hospitalizations) and indirect (lost workdays and intangibles, including lower quality of life and potential consequences of delayed or reduced chemotherapy treatment). Other chemotherapy-associated side effects, such as fatigue, insomnia, or dermatologic conditions, which cannot be easily identified through claims, may also affect treatment adherence.
The nature of the administrative claims database and the lack of granularity precluded us from identifying more than one CINV event per day or the severity of the CINV experienced. While our approach to identify CINV events from claims matches that used in clinical trials of antiemetics, 19, 28 others have used criteria that were either more strict (eg, nausea, vomiting, and dehydration associated with hospital admissions 27 ) or that relied on patient diaries rather than 24, 25 The strategy used in the current study to define CINV did not capture patients using oral antiemetics or over-the-counter remedies, and the IV antiemetics may have been prescribed for reasons other than CINV (eg, for nausea and vomiting associated with migraine, 34 surgery, 35 or gastroparesis 36 ). Nausea and vomiting occurring after day 5 of the chemotherapy cycle and before the subsequent cycle were not attributed to chemotherapy, and may have resulted in an underestimation of CINV events. Despite these limitations, the narrow time frame and broader medical setting used for identifying CINV in the current study design resulted in a conservative estimate of the impact of palonosetron and other 5-HT 3 RAs on CINV in a real-world setting.
Administrative claims are designed for reimbursement rather than research, and may contain coding errors or omissions. Therefore, the claim-based algorithm developed to identify patients with early stage cancers may be susceptible to potential misidentification. Furthermore, standard definitions of adherence with IV chemotherapy regimens within an administrative claim database are lacking in the published literature. All patients were members of large commercial health plans in the US; the results may not be generalizable to patients outside the US or with other types of health insurance. While enrollment was limited to patients with single-day chemotherapy regimens, further research in patients receiving multiday regimens would be desirable. Because of concerns regarding patient selection and cohort size, the comparative analysis was limited to IV chemotherapy in general and IV 5-HT 3 RAs as a class. Consistent with NCCN guideline recommendations, the analysis assumed that the non-5-HT 3 RA components of the observed antiemetic regimens were similar across the palonosetron and other cohorts. NCCN guidelines were used to define chemotherapy regimens for this analysis, and did not allow for individualized treatment plans. BSA was needed to calculate the index dosage of cyclophosphamide and cisplatin; however, this information is unavailable in administrative claims. In the absence of US-based data, BSA estimates developed in a prior UK study 30 were used to calculate index doses.
Conclusion
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